A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis
Status:
RECRUITING
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
A feasibility trial called PROFIT has previously shown that FMT administered endoscopically into the jejunum in patients with cirrhosis is safe and feasible and have identified some potential mechanisms of action that warrant further interrogation. The aim of the PROMISE Trial is to evaluate the efficacy and mechanisms of action of encapsulated FMT (versus placebo) to reduce infection and mortality in patients with alcohol-related and metabolic dysfunction-Associated Steatotic Liver (MASLD) cirrhosis.
Phase:
PHASE3
Details
Lead Sponsor:
King's College London
Collaborators:
BRITISH LIVER TRUST Guy's and St Thomas' NHS Foundation Trust Imperial College London King's College Hospital NHS Trust St George's, University of London